Northwestern University Feinberg School of Medicine

Paul Burridge Lab

News

Read the latest news from the Burridge Lab. The links below take you to articles where you can learn more about our lab’s latest achievements, awards, and honors.

News

  • Hiring New Lab Manager
    04/15/2019
    The Burridge lab is hiring a new lab manager at the Tech II level. Please contact Dr. Burridge for more details. Official advertisement will go live on careers.northwestern.edu soon.
  • Dr. Burridge announced as Associate Editor for the new journal JACC CardioOncology
    03/14/2019
  • Grad School Bonanza: Congratulations to Helen, Mike, Kevin, and Mohammed
    03/11/2019
    Congratulations to Helen (Lab Manager), Mike (MBP Biotech '18), Kevin (MBP Biotech '19), and Mohammed who have all accepted places in PhD or MD programs for the 2019/20 academic year. We'll be sad to see you go but are proud of you all.
  • Postdoctoral Fellow in Stem Cell Biology and Pharmacogenomics
    03/06/2019

    March 6th, 2019: Postdoctoral Fellow in Stem Cell Biology and Pharmacogenomics 

    A postdoctoral position is available in the laboratory of Dr. Paul Burridge in the Department of Pharmacology and the Center for Pharmacogenomics at Northwestern University Feinberg School of Medicine, Chicago, IL.

    Successful candidates will be involved in human induced pluripotent stem cell studies to interrogate how the genome can be used to study disease, predict drug efficacy, minimize toxicity, and discover new drugs.  

    Projects combine patient recruitment, WGS, hiPSC models, RNA-seq, differential expression quantitative trait loci (deQTL) mapping, SNP validation, CRISPR/Cas9-mediated genome editing, and high-throughput drug discovery.

    Major projects available include: 1, Genomics and hiPSC models of chemotherapy-induced toxicity. 2, hiPSC models of breast cancer progression and acquisition of resistance. 3, Genomics of heart failure and cardiomyopathy drug efficacy. 4, Cardiac regenerative medicine including direct reprogramming. 5, hiPSC models of congenital cardiovascular diseases.

    Qualifications: Recent (within the last year) or upcoming PhD or PharmD degree and a strong record of peer-reviewed publications, including first-author, is essential.

    Desirable expertise includes: hiPSC differentiation and/or direct reprogramming methodologies and disease modeling (cardiac, skeletal muscle, endothelial, fibroblast, blood, hepatocyte, renal, neural, cancer cell types, breast epithelial); experience in pharmacogenomics and bioinformatics using next-generation sequencing data types (WGS and RNA-seq); chemotherapy drug response/toxicity mechanisms and GWAS; high-throughput biology and drug screening.

    Good verbal and written communication skills in English are essential. The successful candidate will join a dynamic research environment in the Department of Pharmacology, which offers both basic science and clinical translational opportunities to explore fundamental questions in pharmacogenomics. More details can be found here: http://labs.feinberg.northwestern.edu/burridge/

    Starting salary will be according to NIH (NRSA) Scale and commensurate with experience.

    Please send a CV (including publications), a cover letter containing a brief description of research experience and interests, and a list of 2-3 references to:  paul.burridge@northwestern.edu

    Northwestern University is an Equal Opportunity, Affirmative Action Employer of all protected classes, including veterans and individuals with disabilities. Women and minorities are encouraged to apply. Hiring is contingent upon eligibility to work in the United States.

  • Funding from the National Cancer Institute
    09/13/2018
    The Burridge Lab has been awarded A 5-year NCI R01 Grant for our work the genomic basis of doxorubicin-induced cardiotoxicity